Islet Cell Transplant
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
Coverage criteria for autologous and allogeneic pancreatic islet cell transplantation for Blue Cross Blue Shield - Rhode Island members, with distinctions between BlueCHiP for Medicare and Commercial products.
No material clinical or coverage changes in this revision.
Coverage determinations for islet cell transplantation
Coverage stance by type and product
Coverage determinations:
Evidence from case series and systematic reviews shows the procedure significantly decreases the incidence of diabetes after total or near‑total pancreatectomy and is performed in the context of pancreatectomy for intractable pain.
BCBSRI follows CMS guidelines; billing for investigational clinical services in approved research should follow CMS/BlueCHiP guidance (Q0/Q1 modifiers as applicable).
Randomized and observational evidence is insufficient to determine effects on long‑term outcomes; therefore allogeneic islet transplantation outside approved trials is not covered for Commercial members.
Medicare coverage is limited for pancreatic islet transplantation. Partial pancreatic tissue transplantation or islet transplantation performed outside a clinical trial are not covered by Medicare. Medicare will cover allogeneic islet transplantation only when the procedure is performed as part of a National Institutes of Health (NIH)-sponsored clinical trial.
If a service is determined to be not medically necessary or is a non-covered benefit, coverage may be denied. Providers should confirm member benefits and obtain any required authorizations prior to rendering services to avoid unexpected denials and potential financial liability for the member.
For Commercial products, allogeneic islet transplantation is considered not medically necessary for the treatment of type 1 diabetes due to insufficient evidence of benefit. Specific procedure and HCPCS/CPT codes related to allogeneic islet transplantation (for example, G0341, G0342, G0343, S2102) are listed as not medically necessary for Commercial members.
Services determined to be not medically necessary or otherwise non-covered under the member's plan may result in denial of coverage. Providers must follow the member's subscriber agreement or participation agreement and obtain written member consent if the member agrees to self-pay for non-covered services.
Relevant billing and diagnosis codes
| 48160 | Pancreatectomy, total or subtotal, with autologous transplantation of pancreas or pancreatic islet cells |
| 48999 | Unlisted procedure, pancreas |
| G0341 | Percutaneous islet cell transplant, includes portal vein catheterization and infusion |
| G0342 | Laparoscopy for islet cell transplant, includes portal vein catheterization and infusion |
| G0343 | Laparotomy for islet cell transplant, includes portal vein catheterization and infusion |
| Modifier Q0 | Investigational clinical service provided in a clinical research study (Medicare) |
| Modifier Q1 | Routine clinical service provided in a clinical research study (Medicare) |
| G0341 | Percutaneous islet cell transplant, includes portal vein catheterization and infusion |
| G0342 | Laparoscopy for islet cell transplant, includes portal vein catheterization and infusion |
| G0343 | Laparotomy for islet cell transplant, includes portal vein catheterization and infusion |
| S2102 | Islet cell tissue transplant from pancreas, allogeneic |
| K86.1 | Other chronic pancreatitis (ICD-10 diagnosis linked to covered autologous procedure) |
Eligibility criteria for autologous islet transplantation
Autologous candidate criteria
Candidates for autologous islet transplantation:
Selection is in context of pancreatectomy for intractable pain where benefit (reduced post‑op diabetes) outweighs risks; procedure uses islets isolated from the patient’s resected pancreas and infused into the portal vein.
Provider responsibilities and billing requirements
Check member benefits
Check member benefits — verify Evidence of Coverage / Subscriber Agreement. Benefits and eligibility are determined by the member's subscriber agreement/member certificate and/or the employer agreement; those documents supersede this policy.
- Refer to the member's Evidence of Coverage (EOC) or Subscriber Agreement for specific benefit limitations and exclusions.
- For member-specific eligibility or benefit determinations, contact the provider call center prior to services.
Verify benefits and obtain authorizations
Check member benefits and authorization — contact provider call center prior to services. If services are determined to be not medically necessary or are non-covered, you may be liable for member charges only if the member was informed and agreed in writing in advance.
- Verify prior authorization requirements with the member's plan and obtain any required authorizations before rendering services.
- If a service is non-covered and the member elects to proceed, obtain written agreement from the member acknowledging financial responsibility.
Medicare clinical study billing requirements
Provider action: Billing documentation for Medicare clinical studies — use Q0/Q1 modifiers per BlueCHiP guidance. Claims for services provided as part of a CMS-approved clinical study must include the appropriate modifier; BlueCHiP for Medicare claims filed without the Q0 modifier will deny as not covered.
- Use Modifier Q0 for investigational clinical services provided in an approved clinical research study.
- Use Modifier Q1 for routine clinical services provided in an approved clinical research study.
- Bill HCPCS codes G0341, G0342, G0343 as applicable for islet cell transplant procedures when furnished as part of an approved CMS clinical study.
- Note: HCPCS S2012 is invalid for BlueCHiP for Medicare and should be filed with an alternate code.
Document benefits and eligibility
Provider action: Benefits and eligibility documentation — subscriber/employer agreement supersedes policy. For member-specific coverage or conflicts between this policy and the member's plan documents, the subscriber agreement or employer agreement governs.
- Always document verification of benefits and eligibility in the medical record and practice billing system.
- When in doubt, obtain written confirmation from the payer or plan-specific documentation that supports coverage or non-coverage decisions.
Member financial responsibility risk
Provider action callout — inform members of potential financial responsibility if services are denied. Denial may result in member liability if they have not been informed and agreed in writing to pay for non-covered or not medically necessary services.
- Do not bill the member for services determined not medically necessary unless the member was informed of non-coverage and provided written consent to self-pay.
- Refer to your provider participation agreement for contractual obligations regarding member billing.
Key term definitions
Contraindications
This portion of the policy does not list any explicit absolute or relative contraindications to islet transplantation.
Pre-procedure evaluation and documentation
Evaluation requirements — document clinical indications and prior management
No explicit pre-approval evaluation checklist is provided in this policy; use typical candidate selection criteria (eg, intractable pain, failed medical management for chronic pancreatitis) and document clinical indications thoroughly.
- Document indication: chronic pancreatitis with intractable pain and planned total or near-total pancreatectomy.
- Record prior conservative treatments and rationale for surgical approach.
Facility and program requirements
Center requirements — document procedure location and immunosuppression protocol
Ensure the treating center documents where the procedure was performed (may be in radiology for allogeneic transplants) and documents immunosuppression protocols (eg, Edmonton protocol) when applicable; the policy does not mandate FACT accreditation or volume requirements.
- Document location of procedure (radiology vs operating room) when relevant.
- Document immunosuppression regimen used (Edmonton protocol referenced).
Coverage conditions after transplant
Clinical background
Autologous islet transplantation is performed at the time of total or near-total pancreatectomy for chronic pancreatitis. Islet cells are isolated from the resected pancreas, processed with enzymes, and infused into the patient’s portal vein so implanted beta cells can produce insulin. When performed as an adjunct to pancreatectomy for intractable pain in chronic pancreatitis, the evidence—including case series and systematic reviews—shows a meaningful reduction in the incidence of postoperative diabetes and acceptable safety, supporting coverage of autologous islet transplantation in this setting.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.